Literature DB >> 19191848

Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis.

Michael Karenfort, Bernd C Kieseier, Daniel Tibussek, Birgit Assmann, Joerg Schaper, Ertan Mayatepek.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191848     DOI: 10.1111/j.1469-8749.2008.03246.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


× No keyword cloud information.
  8 in total

1.  Treatment of pediatric multiple sclerosis.

Authors:  Sona Narula; Sarah E Hopkins; Brenda Banwell
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

2.  Therapeutic strategies in childhood multiple sclerosis.

Authors:  Angelo Ghezzi
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 3.  Management of children with multiple sclerosis.

Authors:  E Ann Yeh
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

4.  Current therapeutic options in pediatric multiple sclerosis.

Authors:  E Ann Yeh
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.972

Review 5.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 6.  Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.

Authors:  E Ann Yeh
Journal:  Adolesc Health Med Ther       Date:  2010-07-30

7.  Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis.

Authors:  George Vartzelis; Despoina Maritsi; Maria Nikolaidou; Anastasia Garoufi; Constantinos Kilidireas
Journal:  Case Rep Pediatr       Date:  2019-07-21

8.  Rituximab in paediatric onset multiple sclerosis: a case series.

Authors:  Jonatan Salzer; Jan Lycke; Ronny Wickström; Hans Naver; Fredrik Piehl; Anders Svenningsson
Journal:  J Neurol       Date:  2015-11-24       Impact factor: 6.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.